Perioperative Apalutamide Plus ADT Cuts Metastasis Risk 20% in High-Risk Prostate Cancer
Phase III PROTEUS trial shows adding apalutamide to ADT before and after surgery dramatically improves outcomes in high-risk prostate cancer.
Summary
A major clinical trial called PROTEUS found that combining the drug apalutamide with androgen deprivation therapy (ADT) before and after prostate cancer surgery significantly reduced the risk of cancer spreading. After five-plus years of follow-up, patients on the combination were 20% less likely to experience metastasis or death compared to ADT alone. They were also nine times more likely to have little or no cancer remaining after surgery. Researchers presented these findings at the ASCO annual meeting, with simultaneous publication in the New England Journal of Medicine. Experts are calling it a potential new standard of care for men with high-risk localized prostate cancer who choose surgery.
Detailed Summary
Prostate cancer treatment may be on the verge of a major shift. The phase III PROTEUS trial, presented at the 2026 ASCO annual meeting and published simultaneously in the New England Journal of Medicine, tested whether adding the androgen receptor pathway inhibitor apalutamide to standard androgen deprivation therapy before and after surgery could improve outcomes for men with high-risk localized prostate cancer.
The results were striking. Metastasis-free survival improved from 73.5% with ADT alone to 78.2% with the combination after more than five years of follow-up — a 20% reduced risk of metastasis or death. Equally notable, patients receiving the combination were nine times more likely to achieve a pathologic complete response, meaning little to no detectable cancer remained in the prostate at the time of surgery. Event-free survival and time to distant metastasis or death also improved significantly.
Lead investigator Mary Ellen Taplin, MD, of Dana-Farber Cancer Institute described the findings as a breakthrough in a decades-long treatment paradigm. Patients on the combination therapy went a median of five years before needing any subsequent treatment — a meaningful quality-of-life consideration for men managing this disease long-term.
Experts commenting on the trial suggest it could establish perioperative apalutamide plus ADT as the new standard of care for surgical candidates with high-risk disease. An accompanying editorial in NEJM outlined a future where patients choose between radiotherapy with extended ADT or surgery with 12 months of perioperative apalutamide-ADT — the first neoadjuvant and adjuvant systemic option for this population.
Important caveats remain. Grade 3 or 4 adverse events were more common in the combination arm, driven largely by apalutamide-associated rash. Metastasis-free survival is a surrogate endpoint, and overall survival data are not yet mature. FDA approval is also pending. Men with high-risk localized prostate cancer should discuss these emerging options with their urologist or oncologist.
Key Findings
- Apalutamide plus ADT reduced metastasis or death risk by 20% versus ADT alone after 5+ years.
- Combination therapy produced pathologic complete response in 8.9% vs only 1.0% with ADT alone.
- Patients on the combination did not need subsequent therapy for a median of 5 years.
- Grade 3/4 adverse events were higher in combination arm (39.6% vs 31.0%), mainly due to rash.
- Experts suggest this may become the new standard of care pending FDA approval.
Methodology
This is a meeting coverage news report from MedPage Today summarizing the phase III PROTEUS randomized controlled trial presented at ASCO 2026 and simultaneously published in the New England Journal of Medicine, a high-credibility peer-reviewed journal. The trial involved more than 5 years of follow-up with dual primary endpoints including metastasis-free survival and pathologic complete response.
Study Limitations
Overall survival data are not yet mature; metastasis-free survival is a surrogate endpoint requiring longer follow-up to confirm OS benefit. The article does not report how apalutamide-ADT compares to radiotherapy-based approaches. FDA approval has not yet been granted, so clinical availability may be limited.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.